ColonAiQ®

A Breakthrough in Colorectal Cancer Detection and Surveillance

A cutting-edge, multi-locus blood-based assay specifically targeting circulating tumor DNA methylation. This groundbreaking technology has demonstrated unparalleled success in non-invasive early detection for both colorectal cancer (CRC) and advanced adenoma (AA). ColonAiQ® is poised to redefine the landscape of CRC screening, providing a powerful tool for identifying these conditions at their earliest stages.

ColonAiQ® LTD Test

We are excited to highlight that the groundbreaking ColonAiQ Multi-Gene Methylation Detection Test for Colorectal Cancer (CRC), developed by Singlera Genomics, is now available as a Laboratory Developed Test (LDT) through our esteemed partners, Breakthrough Genomics and Clinomics. This innovative LDT, sets a new standard in the early detection of CRC, one of the most prevalent and lethal cancers worldwide.

For more information on ColonAiQ and how to access this life-saving technology, please visit our partner's websites at Breakthrough Genomics and Clinomics Europe. Join us in embracing this innovative approach to colorectal cancer screening and take a step towards a future where early detection and treatment can save lives.